tiprankstipranks
Lantern Pharma Q2 Results and LP-300 Clinical Trial Update
Company Announcements

Lantern Pharma Q2 Results and LP-300 Clinical Trial Update

Don't Miss our Black Friday Offers:

Lantern Pharma (LTRN) has issued an announcement.

On August 8, 2024, the Company is set to host a conference call and live webinar to discuss its second-quarter financial and operational results, as well as to present details regarding the LP-300 product candidate and its Harmonic™ Phase 2 clinical trial. These discussions aim to provide a comprehensive update to stakeholders and interested parties regarding the company’s recent performance and ongoing research developments.

Learn more about LTRN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyLantern Pharma doses first patient in LP-300 trial expansion cohort
TipRanks Auto-Generated NewsdeskLantern Pharma Discusses Q3 Financial Results Webinar
TipRanks Auto-Generated NewsdeskLantern Pharma Advances AI-Driven Cancer Therapies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App